{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:10:13Z","timestamp":1789729813276,"version":"4.0.1"},"reference-count":46,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2017,1,17]]},"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:p>Interleukin-17 (IL-17A) is a cytokine critical for the acute defence against extracellular bacterial and fungal infections. Excess production during chronic inflammation has been associated with many inflammatory and autoimmune disorders. The present review describes the key molecules of the IL-17 pathway, which are or could be targeted for treatment. Since targeting of IL-17A may affect defence mechanisms, the pathogenesis of such possible adverse events is analysed. Then the contributions of IL-17 to bone changes in various forms of arthritis are discussed. Finally, the results of current inhibitors of the IL-17 pathway in clinical trials are detailed. IL-17A inhibition has been first registered for the treatment of psoriasis, psoriatic arthritis and ankylosing spondylitis. Other therapeutic options are now tested in a long list of diseases.<\/jats:p>","DOI":"10.1136\/rmdopen-2016-000284","type":"journal-article","created":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T20:50:17Z","timestamp":1487191817000},"page":"e000284","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":76,"title":["Update on interleukin-17: a role in the pathogenesis of inflammatory arthritis and implication for clinical practice"],"prefix":"10.1136","volume":"3","author":[{"given":"Pierre","family":"Miossec","sequence":"first","affiliation":[{"name":"Immunogenomics and Inflammation Research Unit EA 4130, Department of Immunology and Rheumatology, University of Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,2,15]]},"reference":[{"key":"2025090312245897000_3.1.e000284.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3794"},{"key":"2025090312245897000_3.1.e000284.2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.6.2593"},{"key":"2025090312245897000_3.1.e000284.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0707449"},{"key":"2025090312245897000_3.1.e000284.4","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.4049\/jimmunol.150.12.5445","article-title":"CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene","volume":"150","author":"Rouvier","year":"1993","journal-title":"J Immunol"},{"key":"2025090312245897000_3.1.e000284.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.502"},{"key":"2025090312245897000_3.1.e000284.6","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199905)42:5<963::AID-ANR15>3.0.CO;2-E"},{"key":"2025090312245897000_3.1.e000284.7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1189\/jlb.71.1.1","article-title":"IL-17: prototype member of an emerging cytokine family","volume":"71","author":"Aggarwal","year":"2002","journal-title":"J Leukoc Biol"},{"key":"2025090312245897000_3.1.e000284.8","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0801967"},{"key":"2025090312245897000_3.1.e000284.9","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.143768"},{"key":"2025090312245897000_3.1.e000284.10","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20061738"},{"key":"2025090312245897000_3.1.e000284.11","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(95)90070-5"},{"key":"2025090312245897000_3.1.e000284.12","doi-asserted-by":"publisher","DOI":"10.1038\/nri2586"},{"key":"2025090312245897000_3.1.e000284.13","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.1.655"},{"key":"2025090312245897000_3.1.e000284.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2007.07.020"},{"key":"2025090312245897000_3.1.e000284.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.07.035"},{"key":"2025090312245897000_3.1.e000284.16","doi-asserted-by":"publisher","DOI":"10.1038\/nature01355"},{"key":"2025090312245897000_3.1.e000284.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.12.004"},{"key":"2025090312245897000_3.1.e000284.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.34565"},{"key":"2025090312245897000_3.1.e000284.19","doi-asserted-by":"publisher","DOI":"10.1186\/ar1020"},{"key":"2025090312245897000_3.1.e000284.20","doi-asserted-by":"publisher","DOI":"10.1126\/science.1200439"},{"key":"2025090312245897000_3.1.e000284.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2009.07.013"},{"key":"2025090312245897000_3.1.e000284.22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.10.6015"},{"key":"2025090312245897000_3.1.e000284.23","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1046-6"},{"key":"2025090312245897000_3.1.e000284.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200468"},{"key":"2025090312245897000_3.1.e000284.25","doi-asserted-by":"publisher","DOI":"10.1097\/01.mca.0000236288.94553.b4"},{"key":"2025090312245897000_3.1.e000284.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(03)00032-8"},{"key":"2025090312245897000_3.1.e000284.27","doi-asserted-by":"publisher","DOI":"10.1186\/ar294"},{"key":"2025090312245897000_3.1.e000284.28","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200106)44:6<1293::AID-ART221>3.0.CO;2-T"},{"key":"2025090312245897000_3.1.e000284.29","doi-asserted-by":"publisher","DOI":"10.1172\/JCI5703"},{"key":"2025090312245897000_3.1.e000284.30","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.5.2655"},{"key":"2025090312245897000_3.1.e000284.31","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3389\/fimmu.2014.00425","article-title":"Effects of interleukin-17A on osteogenic differentiation of isolated human mesenchymal stem cells","volume":"5","author":"Osta","year":"2014","journal-title":"Front Immunol"},{"key":"2025090312245897000_3.1.e000284.32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1205848109"},{"key":"2025090312245897000_3.1.e000284.33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bone.2016.04.008","article-title":"Increased sensitivity of rheumatoid synoviocytes to Schnurri-3 expression in TNF-alpha and IL-17A induced osteoblastic differentiation","volume":"87","author":"Lavocat","year":"2016","journal-title":"Bone"},{"key":"2025090312245897000_3.1.e000284.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2016.01.001"},{"key":"2025090312245897000_3.1.e000284.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"2025090312245897000_3.1.e000284.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512711"},{"key":"2025090312245897000_3.1.e000284.37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824"},{"key":"2025090312245897000_3.1.e000284.38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"2025090312245897000_3.1.e000284.39","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"2025090312245897000_3.1.e000284.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.08.057"},{"key":"2025090312245897000_3.1.e000284.41","doi-asserted-by":"crossref","unstructured":"Glatt S , Helmer E , Haier B , et al . First-in-human randomised study of bimekizumab, a humanised monoclonal antibody and selective dual inhibitor of IL-17A and IL-17 F, in mild psoriasis. Br J Clin Pharmacol 2016. In press. doi:10.1111\/bcp.13185","DOI":"10.1111\/bcp.13185"},{"key":"2025090312245897000_3.1.e000284.42","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cyto.2016.09.019","article-title":"T-cell clones from Th1, Th17 or Th1\/17 lineages and their signature cytokines have different capacity to activate endothelial cells or synoviocytes","volume":"88","author":"Lavocat","year":"2016","journal-title":"Cytokine"},{"key":"2025090312245897000_3.1.e000284.43","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev258"},{"key":"2025090312245897000_3.1.e000284.44","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32833c62b0"},{"key":"2025090312245897000_3.1.e000284.45","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-207110"},{"key":"2025090312245897000_3.1.e000284.46","doi-asserted-by":"crossref","unstructured":"Miossec P . IL-17, now an important target for treatment in arthritis. Joint Bone Spine 2016. In press. doi:10.1016\/j.jbspin.2016.12.001","DOI":"10.1016\/j.jbspin.2016.12.001"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2016-000284","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:25:05Z","timestamp":1756927505000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2016-000284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,15]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,2,15]]},"published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1136\/rmdopen-2016-000284"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2016-000284","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,15]]}}}